| Name | Title | Contact Details |
|---|
Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.
Changing lives with next generation peptide therapeutics
Dax and Lindsay: Thermal Reconditioning Specialists is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arkios BioDevelopment Intl is a Virginia Beach, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Metabolix, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.